Format

Send to

Choose Destination
Gynecol Endocrinol. 2016 Jun;32(6):427-30. doi: 10.3109/09513590.2016.1152240. Epub 2016 Mar 4.

Consensus: soy isoflavones as a first-line approach to the treatment of menopausal vasomotor complaints.

Author information

1
a International Society for Phytosciences , Mattsies , Germany .
2
b Institut Für Pharmazeutische Wissenschaften, Karl-Franzens-Universität Graz , Graz , Austria .
3
c Gynaecological Endocrinonoly and Reproductive Medicine, Medical Faculty, University of Berne , Basel , Switzerland .
4
d Department of Gynaecology and Obstetrics , European Society of Gynecology, University of Pisa , Pisa , Italy .
5
e 1st Department of Gynaeology and Obstetrics, University of Vienna , Wien , Austria .
6
f Chair of Pharmacognostic and Phytochemical Laboratory, Faculty of Pharmacy, University of Ljubljana , Ljubljana , Slovenia .
7
g Division of Obstetrics and Gynadecology , Department of Clinical and Experimental Medicine, Università Di Pisa , Pisa , Italy , and.
8
h Slovenian Menopause Society , Kranj , Slovenia.

Abstract

The association between an increased uptake of isoflavones and a reduced frequency of menopausal hot flushes was first described in 1992, based on a lower incidence of hot flushes in countries with a high consumption of soy. Since then, numerous clinical trials with various sources of isoflavones including soy and red clover have been presented, with practically all of the studies with adequate design delivering an outcome in favour of isoflavone supplementation. An in-depth risk assessment (EFSA 2015) concludes that the amply available human data does not indicate any suspected harmful effects from a potential interaction of isoflavones with hormone-sensitive tissues in the mammary gland, the uterus and the thyroid gland. Safety was ascertained with long-term intake of up to 150 mg isoflavones per day ingested for the duration of at least 3 years. Moreover, high isoflavone intake was found to have preventive effects with respect to breast cancer. Clinical findings indicate potential benefits of isoflavone exposure even during breast cancer treatment with tamoxifen or anastrozole.

KEYWORDS:

Anastrozole; breast cancer; hormone-sensitive tissues; isoflavones; menopausal hot flushes; safety; tamoxifen

PMID:
26943176
DOI:
10.3109/09513590.2016.1152240
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center